Although griseofulvin has only recently become available for general use, Blank1 has studied 31 patients rather extensively and concludes that toxic reactions in man appear to be minimal. Since anti-mitotic effects had been described in rats receiving sublethal doses, these patients were followed carefully for alterations in peripheral blood cell counts. These and other laboratory investigations corroborated the observations that griseofulvin was a drug of relatively low toxicity in man. One patient developed an urticaria-like eruption after five weeks of continuous therapy, and several others noted mild abdominal distress and headache. Pipkin and Ressman2 followed 23 patients receiving griseofulvin and noted a slight depression of the white blood cell count in one-fifth of the children in the group. No other drug eruptions occuring from griseofulvin have been reported to date.
Report of a Case
A 42-year-old white woman has been followed since June 2, 1959, for a moderately